Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LEXXW 
Lexaria Bioscience Corp (LEXXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: LEXXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -16.23% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.79M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.94 | 52 Weeks Range 0.11 - 2.00 | Updated Date 04/17/2025 |
52 Weeks Range 0.11 - 2.00 | Updated Date 04/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1581.04% |
Management Effectiveness
Return on Assets (TTM) -77.6% | Return on Equity (TTM) -145.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 16302820 |
Shares Outstanding - | Shares Floating 16302820 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Lexaria Bioscience Corp
Company Overview
History and Background
Lexaria Bioscience Corp., founded in 2014, focuses on drug delivery innovation. Its core technology, DehydraTECHu2122, improves the way active pharmaceutical ingredients enter the bloodstream. The company has evolved from primarily focusing on cannabinoid delivery to exploring applications across various therapeutic areas.
Core Business Areas
- DehydraTECHu2122 Drug Delivery Technology: Lexaria's primary business revolves around its patented DehydraTECHu2122 technology, which improves the bioavailability and onset speed of orally administered drugs. This includes licensing the technology to other companies and developing its own drug formulations.
Leadership and Structure
Chris Bunka serves as CEO. The company has a board of directors and operates with a structure common to publicly traded biotech companies, including research and development, clinical operations, and intellectual property management divisions.
Top Products and Market Share
Key Offerings
- DehydraTECHu2122 Technology Licensing: Lexaria licenses its DehydraTECHu2122 technology to companies for use in various products, including nicotine pouches and consumer packaged goods containing cannabinoids. Market share data is difficult to obtain due to the varied applications. Competitors in drug delivery technology include NanoSphere Health Sciences and Vesifact.
- DehydraTECH-CBD for Hypertension: Lexaria is developing DehydraTECH-CBD for the treatment of hypertension. This is currently in clinical trials. Market share is non-existent as the product is pre-approval. Competitors include pharmaceutical companies developing other hypertension treatments, such as Novartis and Pfizer.
Market Dynamics
Industry Overview
The pharmaceutical and drug delivery industries are highly competitive and regulated. There is increasing interest in improving drug bioavailability and developing novel drug delivery systems.
Positioning
Lexaria is a niche player focused on improving oral drug delivery using its DehydraTECHu2122 platform. It aims to differentiate itself through improved bioavailability and faster onset of action.
Total Addressable Market (TAM)
The global drug delivery market is estimated at hundreds of billions of dollars. Lexaria targets specific segments within this market, focusing on indications where DehydraTECHu2122 can provide a significant advantage. The exact TAM for Lexaria depends on the specific applications and regulatory approvals secured, however is potentially in the billions.
Upturn SWOT Analysis
Strengths
- Patented DehydraTECHu2122 technology
- Improved drug bioavailability
- Potential for faster onset of action
- Diverse application potential
Weaknesses
- Limited revenue generation
- Reliance on licensing and partnerships
- High cash burn rate
- Clinical trial risks
Opportunities
- Expansion of DehydraTECHu2122 licensing agreements
- Successful clinical trials for hypertension drug
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Regulatory hurdles
- Competition from other drug delivery technologies
- Failure of clinical trials
- Limited funding
Competitors and Market Share
Key Competitors
- ABBV
- PFE
- NVS
Competitive Landscape
Lexaria operates in a highly competitive environment. While DehydraTECH offers potential advantages, it competes against established pharmaceutical companies and other drug delivery technologies. Its success depends on demonstrating clinical efficacy and securing strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on research and development. Revenue growth is expected to be driven by licensing agreements and potential drug approvals.
Future Projections: Future projections depend on clinical trial outcomes, regulatory approvals, and licensing agreements. Analyst estimates are not readily available.
Recent Initiatives: Recent initiatives include advancing clinical trials for DehydraTECH-CBD in hypertension, securing new patent applications, and expanding licensing efforts.
Summary
Lexaria Bioscience Corp. is a development-stage company with potential in its DehydraTECHu2122 technology, but it faces risks associated with clinical trials and funding. The company's success hinges on securing licensing agreements and achieving positive clinical trial outcomes. Key areas to watch are regulatory approvals and expansion into new therapeutic applications. The company's financial stability is crucial for continued operation and development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Lexaria Bioscience Corp. website
- SEC filings
- Market research reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and may not be comprehensive or accurate. Investment decisions should be made based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2021-01-12 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.